Coronavirus Breaking News

The coronavirus disease COVID-19 is currently reaching pandemic levels in various countries.

Apr 1, 2021 • 1:51 pm CDT

Abbott Park-based Abbott announced it had received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter, non-prescription, asymptomatic use its BinaxNOW™ COVID-19 Ag Self Test for detection of COVID-19 infection.

This new indication allows individuals with or without SARS-CoV-2 coronavirus symptoms to have access to this test without a prescription.

Furthermore, Abbott stated in a press release issued on March 31, 2021, it will begin shipping the test to major food, drug, and mass merchandiser retailers in the coming weeks.

And, the test may become available through some online stores.

The test can be used on children as young as two years old when an adult collects samples and for all people aged 15 years or older, bringing the country's most extensively studied and widely used rapid antigen test to nearly everyone in the U.S. The test will come in a two-count box to meet frequent testing requirements.

"We've now accomplished what we set out to do when we launched BinaxNOW, which is to bring an accurate, affordable, and readily available test to the American people that they can have on hand, whether they want to test frequently or in certain circumstances," commented Robert B. Ford, president, and CEO, Abbott.

Abbott initially launched the BinaxNOW professional test nationwide in August 2020 and scaled-up production at its new U.S. manufacturing facilities to produce 50 million tests per month.

The U.S. Department of Health and Human Services purchased the company's first 150 million tests, sending them to K-12 schools, nursing homes, historically black colleges and universities, and underserved communities, where they remain in use today and serve as a powerful tool to help prevent the virus from spreading.

The BinaxNOW Self Test is the same technology as the existing BinaxNOW test.

Using the test will be simple, even for people who have never tested themselves. People will only need to perform a minimally invasive nasal swab (not the deep nasopharyngeal swab). All materials required to perform the test (swab, test card, and reagent solution) will come in the box, says Abbott.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Abbott's portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional, and branded generic medicines. About 109,000 colleagues serve people in more than 160 countries.

Recent data compiled by Statista on March 22, 2021, indicates the USA leads all counties with 371 million COVID-19 tests processed, followed by India (234m) and China (160m).

Medical Review by
Apr 1, 2021 • 7:11 am CDT

The Russian Direct Investment Fund (RDIF) and TopRidge Pharma (a subsidiary company of Tibet Rhodiola Pharmaceutical Holding) announced an agreement on April 1, 2021, to cooperate on the production of over 100 million Sputnik V vaccine doses per year in China.

Additionally, the new agreement empowers TopRidge Pharma to distribute the Sputnik V vaccine in mainland China, Hong Kong, Macao, and Taiwan, subject to all appropriate regulatory approvals.

To date, the two-dose Sputnik V vaccine has been registered in 58 countries globally.

Kirill Dmitriev, CEO of the RDIF, commented in a press release, “Cooperation with Tibet Rhodiola will help increase production capacities of the Sputnik V in China to provide the necessary amounts and help partners in the country and globally to fight the pandemic."

"China is one of the major production hubs for Sputnik V, and we are ready for increasing the scope of partnership with local producers to meet the rising demand for the Russian vaccine, which has an efficacy of 91.6%."

Sputnik V is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

Medical Review by
Mar 31, 2021 • 4:11 pm CDT

The Lancet published the results of the Phase 2/3 study 'Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against the SARS-CoV-2 coronavirus variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial.'

These researchers concluded on March 30, 2021, the 'ChAdOx1 nCoV-19 vaccine (AstraZeneca COVID-19) (Vaxzevria) showed reduced neutralization activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2.'

These findings show that while laboratory neutralizing antibody titers generated by vaccination with ChAdOx1 nCoV-19 vaccine are lower for the B.1.1.7 lineage, clinical vaccine efficacy against symptomatic COVID-19 was observed for the B.1.1.7 variant at 70.4%.

This suggests that lower neutralizing antibody titers are sufficient to provide protection or that other immune mechanisms could be responsible for protecting disease in vaccinated individuals.

The Vaxzevria - AstraZeneca COVID-19 vaccine efficacy against this new variant is an important finding for regions where B.1.1.7 is now the dominant variant, and vaccination programs are already underway, concluded these researchers.

Vaxzevria is the new global name for the AstraZeneca COVID-19 vaccine.

Medical Review by
Mar 31, 2021 • 11:11 am CDT

The US Centers for Disease Control and Prevention updated its website on March 29, 2021, stating, 'There is not enough data to show whether people with diabetes are more likely to get COVID-19 than the general population.'

'But, having either type 1 or type 2 diabetes can make you more likely to get severely ill from COVID-19.'

The American Diabetes Association (ADA) says, 'It’s important to remember that people with either type of diabetes can vary in their age, complications they’ve developed and how well they have been able to manage their diabetes.'

'People who already have diabetes-related health problems are likely to have worse outcomes if they contract COVID-19 than people with diabetes who are otherwise healthy, whichever type of diabetes they have.'

'Your risk of getting very sick from COVID-19 is likely to be lower if your diabetes is well-managed. Having heart disease or other complications in addition to diabetes could worsen the chance of getting seriously ill from COVID-19, like other viral infections, because more than one condition makes it harder for your body to fight the infection,' adds the ADA's website.

Medical Review by
Mar 31, 2021 • 10:08 am CDT

The European Medicines Agency (EMA) safety committee met on March 31, 2021, in the context of its ongoing review of very rare cases of unusual blood clots associated with low numbers of platelets in people vaccinated with AstraZeneca’s COVID-19 vaccine (now called Vaxzevria).

The EMA stated 'At present, the review has not identified any specific risk factors, such as age, gender, or a previous medical history of clotting disorders, for these very rare events. A causal link with the vaccine is not proven but is possible, and further analysis is continuing.'

Furthermore, as communicated on March 18th, the 'EMA is of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalization and death, outweigh the risks of side effects.'

However, vaccinated people should be aware of the remote possibility of these very rare types of blood clots occurring. If they have symptoms suggestive of clotting problems as described in the product information, they should seek immediate medical attention and inform healthcare professionals of their recent vaccination, says the EMA.

'EMA continues to work with the national authorities in the EU Member States to ensure that suspected cases of unusual blood clots are reported; these cases are being analyzed in ongoing assessments. Based on all the currently available data, the committee is expected to issue an updated recommendation during its April plenary meeting (6–9 April).

More information and advice for healthcare professionals and the public is available in the vaccine’s product information and direct healthcare professional communication.

Based in The Netherlands, the mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union.

Medical Review by
Mar 30, 2021 • 11:28 am CDT

The Governor of Texas announced the creation of a COVID-19 Rapid Testing Program for youth summer camps. This program will help summer camps licensed by the Texas Department of State Health Services (DSHS) to conduct rapid tests of staff and campers during the summer months.

"As normalcy returns to Texas, we must remain vigilant against the spread of COVID-19 by identifying positive cases and mitigating any potential outbreaks throughout the state," said Texas Governor Greg Abbott in a press statement issued on March 30, 2021.

"The COVID-19 Testing Program for Texas Youth Summer Camps will help camps safely operate throughout the summer by quickly identifying positive COVID-19 cases among campers and staff. I encourage qualifying summer camps to apply for this program so that we can continue to keep Texans safe from this virus."

Youth summer camps licensed by DSHS and those who wish to participate in the program can apply at this link.

Medical Review by
Mar 29, 2021 • 6:13 pm CDT

Prince Edward Island's Chief Public Health Officer, Dr. Heather Morrison, announced today that Prince Edward Island (PEI) would pause the administration of the AstraZeneca COVID-19 vaccine (Vaxzevria) for those under 55 years of age in the Candian province.

A total of 1,680 doses of the AstraZeneca vaccine have been administered in PEI. Those who have received the vaccine are asked to seek immediate medical attention if they experience related symptoms between 4 and 20 days after receiving the AstraZeneca vaccine.

“The risk of developing a health problem after being immunized is very low, and serious side effects are extremely rare. We take vaccine safety very seriously and believe this is the right decision at this time,” said Dr. Morrison in a press statement.

“The vaccine remains an important layer of protection against this virus, and I urge all Islanders to continue to be eager and enthusiastic to be vaccinated against COVID-19.”

Earlier today, the National Advisory Committee on Immunization recommended an immediate pause in using the AstraZeneca vaccine in individuals under 55 years of age in Canada. The recommendation follows European reports of very rare, but serious, cases of blood clots associated with low levels of blood platelets following immunization with the AstraZeneca vaccine. No blood clotting abnormalities have not been reported throughout Canada.

Medical Review by
Mar 29, 2021 • 5:23 pm CDT

The National Football League recently announced it would reduce COVID-19 restrictions by allowing fully vaccinated individuals participating in college draft to remain maskless if all others in the room are vaccinated.

The 2021 NFL Draft will take place in Cleveland, Ohio, on April 29, 2021, and run through May 1st.

The last 2020 event was the first completely virtual NFL draft.

The relaxed measures, including minimal distancing, will only apply to those with proof of vaccination.

In order to be classified as fully vaccinated, the individual must have received two doses of the Moderna or Pfizer vaccines and completed the requisite two-week post-shot period, or have received the Johnson & Johnson Janssen COVID-19 vaccine and completed the requisite two-week post-shot period per the NFL memo.

The NFL memo also allows for a maximum of 10 fully vaccinated individuals in the draft room. If all individuals are fully vaccinated, masks will not be required, physical distancing measures will be relaxed, and eating and drinking will be permissible.

The new update from NFL officials details the changes to the guidelines and procedures, which NFL Network reporter Ian Rapoport shared via Twitter.

The NFL has not clarified requirements for fans, employees, and players in the upcoming season with regards to capacity limits and vaccination requirements.

Medical Review by
Mar 29, 2021 • 12:32 pm CDT

London-based GlaxoSmithKline (GSK) announced today an agreement in principle with Maryland-based Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of the Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK.

GSK stated it would provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021. To be provided by GSK, fill and finish is the completion stage of vaccine manufacturing, preparing vials of the final vaccine and packaging them for distribution and use.

The GSK site at Barnard Castle, which will deliver the vaccine doses under this collaboration, is a specialized facility in GSK’s global manufacturing network, supporting the production of GSK pharmaceutical and vaccine products.

The protein antigen component of NVX-CoV2373 is also produced in the North East of England by Novavax’s manufacturing partner, FUJIFILM Diosynth Biotechnologies, at their site in Billingham, Stockton-on-Tees.

The Novavax vaccine candidate has demonstrated strong potential efficacy in Phase 3 clinical trials, including against the B.1.1.7 variant circulating in the UK. Submission of the vaccine for review by regulatory authorities in the UK is expected during the second quarter.

Roger Connor, President, GSK Vaccines, commented in a press release issued on March 29, 2021, “GSK is delighted to support Novavax and the UK Vaccines Taskforce with this manufacturing arrangement for the UK, and our Barnard Castle facility is now undertaking the rapid preparation work required to manufacture up to 60m doses of this vaccine. We have ensured that we can deliver these volumes without impacting the supply of our other vital medicines and vaccines, and without disruption, to the other COVID-19 collaborations GSK is engaged in globally.”

The UK Government previously secured 60 million doses of the vaccine under an advance purchase agreement with Novavax.

GSK is collaborating with several organizations worldwide on COVID-19 vaccines by providing access to our adjuvant technology.

Medical Review by
Mar 28, 2021 • 8:07 am CDT

BioNTech SE announced on March 26, 2021, that the European Medicines Agency (EMA) approved the manufacturing of the Comirnaty COVID-19 vaccine drug product at the facility in Marburg, Germany.

The approvals make BioNTech’s Marburg manufacturing site one of the largest mRNA vaccine manufacturing sites in Europe as well as worldwide with an annual production capacity of up to one billion doses of our COVID-19 vaccine, once fully operational.

Furthermore, because of optimized operational efficiencies initiated in 2020, BioNTech has been able to increase the expected annual manufacturing capacity by 250 million doses.

'Together with our partner Pfizer, we are working continuously on multiple initiatives to respond to global demand,' stated the BioNTech press statement.

The Pfizer-BioNTech COVID-19 vaccine, which is known globally as Comirinaty, is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada, and other countries in advance of a planned application for full marketing authorizations in these countries.

Medical Review by
Mar 26, 2021 • 4:40 pm CDT

The US Centers for Disease Control and Prevention (CDC) continue to report significant decreases in the COVID-19 pandemic. As of March 26, 2021, the CDC confirmed the number of COVID-19 related fatalities has continued to decline, a trend observed over the past 10 weeks.

The current 7-day moving average of new fatalities (946) in the USA decreased by 72% compared with the highest peak on January 13, 2021.

And hospital admissions of patients with confirmed COVID-19 decreased 71.5% from the national peak on January 9, 2021.

Furthermore, the CDC reported 48,695,172 individuals are now fully-vaccinated against COVID-19.

People who are fully vaccinated represent the number of people who have received the second dose in a two-dose COVID-19 vaccine series or one dose of the single-shot Janssen COVID-19 vaccine, says the CDC.

Globally, the World Health Organization (WHO) confirmed on March 23, 2021, coronavirus cases continued to rise for a fourth consecutive week, with just under 3.3 million new cases reported in the last week.

Concurrently, the number of new fatalities reported plateaued after a six-week decrease, with just over 60,000 new fatalities reported. The European Region and the Southern Region of the Americas continue to account for nearly 80% of all the COVID-19 cases and fatalities, stated the WHO.

Mar 26, 2021 • 5:20 am CDT

Hyderabad - based Dr. Reddy’s Laboratories confirmed it had submitted phase 2 and 3 clinical study data to the Drug Controller General of India as requested and awaits final review. If approved, 100 million doses of the Sputnick V vaccine would become available in India, reported the Times of India on March 25, 2021.

Recently, India-based Gland Pharma Ltd. announced an agreement with the Russian Direct Investment Fund to produce and supply up to 25.2 doses of the Sputnik V vaccine during 2021.

In total, 56 countries had authorized the Sputnik V Vaccine as of March 25, 2021.

Research studies have shown the Sputnik V (Gam-COVID-Vac) vaccine reduces the time for the development of immunity to SARS-CoV-2, the beta coronavirus that causes COVID-19 in people.

Medical Review by
Mar 25, 2021 • 7:51 am CDT

The Russian Direct Investment Fund (RDIF) announced on March 25, 2021, the Republic of Serbia will become the first state in Southern Europe to produce the Sputnik V vaccine.

The Torlak Institute of Virology, Vaccines, and Serums will begin producing the vaccine in May 2021. The Torlak Institute is a state-owned manufacturer and supplier of vaccines to medical institutions in Serbia.

Nenad Popovic, Minister of Innovation and Technological Development, Co-Chairman of the Intergovernmental Committee for Cooperation between the Russian Federation and Serbia, noted in a press statement, "The production of the Sputnik V vaccine by the Torlak Institute will expand the capabilities of our country in the fight against coronavirus and open up new prospects for the supply of the vaccine to other countries of Southern Europe."

"The transfer of technology for the production of Sputnik V in Serbia will strengthen our sovereignty in the field of vaccine production. In the future, this area will be of great importance for every country ”.

The first batch of the Sputnik V vaccine was delivered to Serbia on December 30, 2020. Vaccination programs began in Serbia on January 6, 2021.

To date, the Sputnik V vaccine has been registered in 56 countries, stated the RDIF.

Mar 24, 2021 • 5:01 pm CDT

An emerging leader in non-invasive medical diagnostics, Know Labs, Inc., shared with the public preliminary study results from Texas Biomedical Research Institute (Texas Biomed) indicating the Particle bulb’s ability to inactivate SARS-CoV-2, the coronavirus that causes COVID-19.

Multiple tests performed by Texas Biomed demonstrated a 95% reduction in the SARS-CoV-2 virus after 5 hours of exposure to the Particle bulb; a 99% reduction in 6 hours; and a 99.9% reduction in 8 hours.

Rather than using dangerous UV-C light to kill germs quickly, Particle’s method is “low and slow.” Particle bulb disinfects germs using Gentle UV, a blend of UV-A light, for longer periods, allowing it to be used safely near people in homes, businesses, and institutions.

“We were very pleased to work with Texas Biomed because of their reputation as a global leader in eradicating infectious diseases and we’re really excited by these results,” stated Know Labs CEO, Phil Bosua, in a media statement.

In addition, the Particle bulb can kill a number of common household bacteria and germs, for example, E. Coli, Salmonella, and Staphylococcus.

San Antonio, TX-based Texas Biomed is a world-renowned, independent, non-profit biomedical research institute specializing in infectious diseases.

Medical Review by
Mar 24, 2021 • 12:48 pm CDT

The Russian Direct Investment Fund (RDIF) and the ChemRar Group announce on March 24, 2021, that the Favipiravir-based drug Avifavir has been registered by the National Agency of Drug and Food Control of Indonesia. Pratapa Nirmala-Fahrenheit is the partner for the registration and sales of Avifavir in Indonesia.

Avifavir was registered in Indonesia under an accelerated procedure based on data obtained during an extended phase II-III clinical trial, which took place in compliance between April-September 2020, at 30 specialized centers throughout Russia, involving 460 patients. Efficacy of the drug was above 80%, the criterion for a drug with high antiviral activity;

Avifavir is the first Favipiravir-based drug approved for the treatment of COVID-19.

Kirill Dmitriev, CEO of the RDIF, stated in a press release, “Experts in Indonesia have shown high confidence in the drug, which is registered without additional clinical trials in the country. Avifavir significantly reduces the recovery time and has high efficiency, allowing faster treatment of patients and significantly reducing the burden on medical institutions. "

The Russian Ministry of Health has included Avifavir in the list of vital and essential medicines and the guidelines for preventing, diagnosing, and treating new SARS-CoV-2 coronavirus infections.

Since June 2020, Avifavir has been supplied to all regions of the Russian Federation, and it has been supplied to 15 countries globally.

Favipiravir-based drugs are sold under various names worldwide, such as Avigan, FabiFlu, Avifavir, Ciplenza, FluGuard, Avifavir, Coronavir, and Reeqonus in Canada.

Japan-based Toyama Chemical Co., Ltd. discovered Avigan (favipiravir), which selectively inhibits RNA polymerase necessary for influenza virus replication.